130
Participants
Start Date
August 22, 2024
Primary Completion Date
July 31, 2026
Study Completion Date
July 31, 2026
OPN-6602
orally active, small molecule inhibitor of EP300 and CBP bromodomain; dosed daily
Dexamethasone
Synthetic glucocorticoid; 40 mg Days 1, 8, 15 of each cycle
RECRUITING
University of Rochester Medical Center, Rochester
RECRUITING
Emory Winchip Cancer Center, Atlanta
RECRUITING
Karmanos Cancer Institute, Detroit
RECRUITING
START Midwest, Grand Rapids
RECRUITING
University of Kansas Clinical Research Center, Westwood
RECRUITING
Huntsman Cancer Center Institute University of Utah, Salt Lake City
RECRUITING
Banner MD Anderson, Gilbert
RECRUITING
Stanford Cancer Institute, Stanford
RECRUITING
Fred Hutchinson Cancer Center, Seattle
RECRUITING
Dana Farber Cancer Institute, Boston
Lead Sponsor
Opna Bio LLC
INDUSTRY